29th Sep 2023 9:30 am |
RNS |
Total Voting Rights |
14th Sep 2023 9:30 am |
RNS |
Director’s Share Dealing |
12th Sep 2023 9:30 am |
RNS |
Phase IIIb Savolitinib Results at WCLC 2023 |
12th Sep 2023 7:00 am |
RNS |
Patient Enrollment Completed for Bridging Study |
31st Aug 2023 9:30 am |
RNS |
Total Voting Rights |
29th Aug 2023 7:00 am |
RNS |
BTD in China for Savolitinib for Gastric Cancer |
21st Aug 2023 7:00 am |
RNS |
Sovleplenib Phase 3 Study Meets Primary Endpoint |
7th Aug 2023 9:30 am |
RNS |
Exercise of Share Options by a Director |
31st Jul 2023 12:00 pm |
RNS |
Interim Results and Business Updates |
20th Jul 2023 7:00 am |
RNS |
Breakthrough Therapy Designation for Fruquintinib |
13th Jul 2023 9:30 am |
RNS |
Changes to Board and Technical Committee |
10th Jul 2023 7:00 am |
RNS |
Phase 1 Study of HMPL-415 Initiated |
29th Jun 2023 9:30 am |
RNS |
Blocklisting Six Monthly Return |
26th Jun 2023 9:30 am |
RNS |
HUTCHMED to Announce 2023 Half-Year Results |
16th Jun 2023 7:00 am |
RNS |
Phase III FRESCO-2 Results in The Lancet |
15th Jun 2023 3:39 pm |
RNS |
MAA of Fruquintinib Validated by the EMA |
9th Jun 2023 10:30 am |
RNS |
HUTCHMED Highlights Presentations at EHA and ICML |
6th Jun 2023 10:00 am |
RNS |
LTIP and Share Option Scheme |
31st May 2023 9:30 am |
RNS |
Total Voting Rights |
26th May 2023 7:00 am |
RNS |
Fruquintinib NDA Granted Priority Review by FDA |
26th May 2023 7:00 am |
RNS |
HUTCHMED Highlights Presentations at ASCO 2023 |
17th May 2023 9:30 am |
RNS |
Standard form for notification of major holdings |
12th May 2023 1:15 pm |
RNS |
Annual General Meeting Poll Results |
12th May 2023 9:30 am |
RNS |
Board of Directors and Board Committee Membership |
10th May 2023 9:30 am |
RNS |
Appointment of Independent NED |
28th Apr 2023 9:30 am |
RNS |
Total Voting Rights |
21st Apr 2023 9:30 am |
RNS |
Vesting of awards under the LTIP |
18th Apr 2023 7:00 am |
RNS |
NDA Acceptance in China for Fruquintinib |
12th Apr 2023 7:00 am |
RNS |
Presentations at AACR Annual Meeting 2023 |
11th Apr 2023 9:30 am |
RNS |
Intended Retirement of Independent NED |
11th Apr 2023 9:30 am |
RNS |
2022 Annual Report and Notice of AGM |
4th Apr 2023 10:30 am |
RNS |
HUTCHMED Initiates Registration Phase Enrollments |
31st Mar 2023 9:30 am |
RNS |
Total Voting Rights |
31st Mar 2023 7:00 am |
RNS |
Rolling Submission of Fruquintinib US NDA Complete |
14th Mar 2023 1:30 pm |
RNS |
Closing of Fruquintinib License to Takeda |
8th Mar 2023 8:30 am |
RNS |
Director's Share Dealing |
6th Mar 2023 8:30 am |
RNS |
Vesting of awards under the LTIP |
28th Feb 2023 12:15 pm |
RNS |
Publication of Form 20-F |
28th Feb 2023 8:30 am |
RNS |
2022 Full Year Results and Business Updates |
27th Feb 2023 10:00 am |
RNS |
Enrollment Completed in Phase 2 Amdizalisib trial |